Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2046559
Max Phase: Preclinical
Molecular Formula: C38H50O9
Molecular Weight: 650.81
Molecule Type: Small molecule
Associated Items:
ID: ALA2046559
Max Phase: Preclinical
Molecular Formula: C38H50O9
Molecular Weight: 650.81
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(/C=C/C(=O)O[C@H]2CC[C@@]3(C)C(=CC[C@]4(O)[C@@H]3C[C@@H](OC(=O)/C=C(\C)C(C)C)[C@@]3(C)[C@]4(O)CC[C@@]3(O)C(C)=O)C2)cc1
Standard InChI: InChI=1S/C38H50O9/c1-23(2)24(3)20-33(41)47-31-22-30-34(5)16-15-29(46-32(40)13-10-26-8-11-28(45-7)12-9-26)21-27(34)14-17-37(30,43)38(44)19-18-36(42,25(4)39)35(31,38)6/h8-14,20,23,29-31,42-44H,15-19,21-22H2,1-7H3/b13-10+,24-20+/t29-,30+,31+,34-,35+,36+,37-,38+/m0/s1
Standard InChI Key: SEXRIOKVROQFNA-GAKBQJCISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 650.81 | Molecular Weight (Monoisotopic): 650.3455 | AlogP: 5.26 | #Rotatable Bonds: 8 |
Polar Surface Area: 139.59 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.39 | CX Basic pKa: | CX LogP: 5.19 | CX LogD: 5.19 |
Aromatic Rings: 1 | Heavy Atoms: 47 | QED Weighted: 0.20 | Np Likeness Score: 2.31 |
1. Wang LJ, Geng CA, Ma YB, Luo J, Huang XY, Chen H, Zhou NJ, Zhang XM, Chen JJ.. (2012) Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents., 54 [PMID:22687441] [10.1016/j.ejmech.2012.05.012] |
2. Huang LJ, Chen SR, Yuan CM, Gu W, Guo BJ, Wang YT, Wang Y, Hao XJ.. (2017) C21-steroidal pregnane sapogenins and their derivatives as anti-inflammatory agents., 25 (13): [PMID:28506585] [10.1016/j.bmc.2017.04.045] |
Source(1):